Global Metabolic Disorders Drugs Market

Metabolic Disorders Drugs Comprehensive Study by Type (Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug, Amino Acid Metabolism Drug), Application (Hospital, Retail Pharmacy), Route of Administration (Inhalation, Injection, Other) Players and Region - Global Market Outlook to 2030

Metabolic Disorders Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Metabolic Disorders Drugs
A metabolic disorder occurs when abnormal chemical reactions in the body disrupt the body process. Increasing incidences of Inherited metabolic diseases due to changing lifestyles and rising number of diabetic patients boosting the Metabolic Disorders Drug market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global metabolic disorders drug market is fragmented with numerous market players. Due to the rising drug approvals, mid-size to smaller companies are increasing their market presence by introducing new ingredients with fewer prices. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Metabolic Disorders Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck & Co., Inc (United States), Novartis International AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca plc (United Kingdom), C.H. Boehringer Sohn AG & Ko. KG (Germany), Kowa Pharmaceuticals America, Inc (United States), LG Life Science (South Korea) and Mitsubishi Tanabe Pharma Corporation (Japan) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Metabolic Disorders Drugs market by Type (Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug and Amino Acid Metabolism Drug), Application (Hospital and Retail Pharmacy) and Region.



On the basis of geography, the market of Metabolic Disorders Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Inhalation will boost the Metabolic Disorders Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancements in Drug Delivery Technologies

Market Growth Drivers:
Increasing incidences of Inherited Metabolic Diseases due to Changing Lifestyles and Rising Number of Diabetic Patients

Challenges:
Side Effects of the Drugs

Restraints:
Straight Government Regulation Related to Drug Production

Opportunities:
High Healthcare Expenditure and Raising Awareness about Metabolic Disorder in Developing Countries and Growing Healthcare Infrastructure in the Developing Economies

Market Leaders and their expansionary development strategies
In August 2017, Boehringer Ingelheim and pharmaceutical company Pharmaxis announced that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335, acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3)1, and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.
In February 2024, India's Zydus Lifesciences is aiming to launch its first new drug in the United States by early 2026, looking to tap into the multi-billion dollar market for treating a type of liver disease, Managing Director Sharvil Patel told Reuters.


Key Target Audience
Metabolic Disorders Drugs Manufacturers, Metabolic Disorders Drugs Suppliers, Medical Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Potential Investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Glycogen Metabolism Disease Drug
  • Lipid Metabolism Disease Drug
  • Amino Acid Metabolism Drug
By Application
  • Hospital
  • Retail Pharmacy
By Route of Administration
  • Inhalation
  • Injection
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing incidences of Inherited Metabolic Diseases due to Changing Lifestyles
      • 3.2.2. Rising Number of Diabetic Patients
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of the Drugs
    • 3.4. Market Trends
      • 3.4.1. Advancements in Drug Delivery Technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Metabolic Disorders Drugs, by Type, Application, Route of Administration and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Metabolic Disorders Drugs (Value)
      • 5.2.1. Global Metabolic Disorders Drugs by: Type (Value)
        • 5.2.1.1. Glycogen Metabolism Disease Drug
        • 5.2.1.2. Lipid Metabolism Disease Drug
        • 5.2.1.3. Amino Acid Metabolism Drug
      • 5.2.2. Global Metabolic Disorders Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Retail Pharmacy
      • 5.2.3. Global Metabolic Disorders Drugs by: Route of Administration (Value)
        • 5.2.3.1. Inhalation
        • 5.2.3.2. Injection
        • 5.2.3.3. Other
      • 5.2.4. Global Metabolic Disorders Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Metabolic Disorders Drugs (Volume)
      • 5.3.1. Global Metabolic Disorders Drugs by: Type (Volume)
        • 5.3.1.1. Glycogen Metabolism Disease Drug
        • 5.3.1.2. Lipid Metabolism Disease Drug
        • 5.3.1.3. Amino Acid Metabolism Drug
      • 5.3.2. Global Metabolic Disorders Drugs by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Retail Pharmacy
      • 5.3.3. Global Metabolic Disorders Drugs by: Route of Administration (Volume)
        • 5.3.3.1. Inhalation
        • 5.3.3.2. Injection
        • 5.3.3.3. Other
      • 5.3.4. Global Metabolic Disorders Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Metabolic Disorders Drugs (Price)
      • 5.4.1. Global Metabolic Disorders Drugs by: Type (Price)
  • 6. Metabolic Disorders Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. C.H. Boehringer Sohn AG & Ko. KG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kowa Pharmaceuticals America, Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. LG Life Science (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Metabolic Disorders Drugs Sale, by Type, Application, Route of Administration and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Metabolic Disorders Drugs (Value)
      • 7.2.1. Global Metabolic Disorders Drugs by: Type (Value)
        • 7.2.1.1. Glycogen Metabolism Disease Drug
        • 7.2.1.2. Lipid Metabolism Disease Drug
        • 7.2.1.3. Amino Acid Metabolism Drug
      • 7.2.2. Global Metabolic Disorders Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Retail Pharmacy
      • 7.2.3. Global Metabolic Disorders Drugs by: Route of Administration (Value)
        • 7.2.3.1. Inhalation
        • 7.2.3.2. Injection
        • 7.2.3.3. Other
      • 7.2.4. Global Metabolic Disorders Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Metabolic Disorders Drugs (Volume)
      • 7.3.1. Global Metabolic Disorders Drugs by: Type (Volume)
        • 7.3.1.1. Glycogen Metabolism Disease Drug
        • 7.3.1.2. Lipid Metabolism Disease Drug
        • 7.3.1.3. Amino Acid Metabolism Drug
      • 7.3.2. Global Metabolic Disorders Drugs by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Retail Pharmacy
      • 7.3.3. Global Metabolic Disorders Drugs by: Route of Administration (Volume)
        • 7.3.3.1. Inhalation
        • 7.3.3.2. Injection
        • 7.3.3.3. Other
      • 7.3.4. Global Metabolic Disorders Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Metabolic Disorders Drugs (Price)
      • 7.4.1. Global Metabolic Disorders Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Metabolic Disorders Drugs: by Type(USD Million)
  • Table 2. Metabolic Disorders Drugs Glycogen Metabolism Disease Drug , by Region USD Million (2018-2023)
  • Table 3. Metabolic Disorders Drugs Lipid Metabolism Disease Drug , by Region USD Million (2018-2023)
  • Table 4. Metabolic Disorders Drugs Amino Acid Metabolism Drug , by Region USD Million (2018-2023)
  • Table 5. Metabolic Disorders Drugs: by Application(USD Million)
  • Table 6. Metabolic Disorders Drugs Hospital , by Region USD Million (2018-2023)
  • Table 7. Metabolic Disorders Drugs Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 8. Metabolic Disorders Drugs: by Route of Administration(USD Million)
  • Table 9. Metabolic Disorders Drugs Inhalation , by Region USD Million (2018-2023)
  • Table 10. Metabolic Disorders Drugs Injection , by Region USD Million (2018-2023)
  • Table 11. Metabolic Disorders Drugs Other , by Region USD Million (2018-2023)
  • Table 12. South America Metabolic Disorders Drugs, by Country USD Million (2018-2023)
  • Table 13. South America Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 14. South America Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 15. South America Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 16. Brazil Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 17. Brazil Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 18. Brazil Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 19. Argentina Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 20. Argentina Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 21. Argentina Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 22. Rest of South America Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 23. Rest of South America Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 24. Rest of South America Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 25. Asia Pacific Metabolic Disorders Drugs, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 27. Asia Pacific Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 28. Asia Pacific Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 29. China Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 30. China Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 31. China Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 32. Japan Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 33. Japan Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 34. Japan Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 35. India Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 36. India Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 37. India Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 38. South Korea Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 39. South Korea Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 40. South Korea Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 41. Taiwan Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 42. Taiwan Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 43. Taiwan Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 44. Australia Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 45. Australia Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 46. Australia Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 50. Europe Metabolic Disorders Drugs, by Country USD Million (2018-2023)
  • Table 51. Europe Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 52. Europe Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 53. Europe Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 54. Germany Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 55. Germany Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 56. Germany Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 57. France Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 58. France Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 59. France Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 60. Italy Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 61. Italy Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 62. Italy Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 63. United Kingdom Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 64. United Kingdom Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 65. United Kingdom Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 66. Netherlands Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 67. Netherlands Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 68. Netherlands Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 69. Rest of Europe Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 70. Rest of Europe Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 71. Rest of Europe Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 72. MEA Metabolic Disorders Drugs, by Country USD Million (2018-2023)
  • Table 73. MEA Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 74. MEA Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 75. MEA Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 76. Middle East Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 77. Middle East Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 78. Middle East Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 79. Africa Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 80. Africa Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 81. Africa Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 82. North America Metabolic Disorders Drugs, by Country USD Million (2018-2023)
  • Table 83. North America Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 84. North America Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 85. North America Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 86. United States Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 87. United States Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 88. United States Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 89. Canada Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 90. Canada Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 91. Canada Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 92. Mexico Metabolic Disorders Drugs, by Type USD Million (2018-2023)
  • Table 93. Mexico Metabolic Disorders Drugs, by Application USD Million (2018-2023)
  • Table 94. Mexico Metabolic Disorders Drugs, by Route of Administration USD Million (2018-2023)
  • Table 95. Metabolic Disorders Drugs Sales: by Type(K Unit)
  • Table 96. Metabolic Disorders Drugs Sales Glycogen Metabolism Disease Drug , by Region K Unit (2018-2023)
  • Table 97. Metabolic Disorders Drugs Sales Lipid Metabolism Disease Drug , by Region K Unit (2018-2023)
  • Table 98. Metabolic Disorders Drugs Sales Amino Acid Metabolism Drug , by Region K Unit (2018-2023)
  • Table 99. Metabolic Disorders Drugs Sales: by Application(K Unit)
  • Table 100. Metabolic Disorders Drugs Sales Hospital , by Region K Unit (2018-2023)
  • Table 101. Metabolic Disorders Drugs Sales Retail Pharmacy , by Region K Unit (2018-2023)
  • Table 102. Metabolic Disorders Drugs Sales: by Route of Administration(K Unit)
  • Table 103. Metabolic Disorders Drugs Sales Inhalation , by Region K Unit (2018-2023)
  • Table 104. Metabolic Disorders Drugs Sales Injection , by Region K Unit (2018-2023)
  • Table 105. Metabolic Disorders Drugs Sales Other , by Region K Unit (2018-2023)
  • Table 106. South America Metabolic Disorders Drugs Sales, by Country K Unit (2018-2023)
  • Table 107. South America Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 108. South America Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 109. South America Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 110. Brazil Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 111. Brazil Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 112. Brazil Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 113. Argentina Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 114. Argentina Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 115. Argentina Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 116. Rest of South America Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 117. Rest of South America Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 118. Rest of South America Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 119. Asia Pacific Metabolic Disorders Drugs Sales, by Country K Unit (2018-2023)
  • Table 120. Asia Pacific Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 121. Asia Pacific Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 122. Asia Pacific Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 123. China Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 124. China Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 125. China Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 126. Japan Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 127. Japan Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 128. Japan Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 129. India Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 130. India Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 131. India Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 132. South Korea Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 133. South Korea Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 134. South Korea Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 135. Taiwan Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 136. Taiwan Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 137. Taiwan Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 138. Australia Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 139. Australia Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 140. Australia Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 141. Rest of Asia-Pacific Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 142. Rest of Asia-Pacific Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 143. Rest of Asia-Pacific Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 144. Europe Metabolic Disorders Drugs Sales, by Country K Unit (2018-2023)
  • Table 145. Europe Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 146. Europe Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 147. Europe Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 148. Germany Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 149. Germany Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 150. Germany Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 151. France Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 152. France Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 153. France Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 154. Italy Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 155. Italy Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 156. Italy Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 157. United Kingdom Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 158. United Kingdom Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 159. United Kingdom Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 160. Netherlands Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 161. Netherlands Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 162. Netherlands Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 163. Rest of Europe Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 164. Rest of Europe Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 165. Rest of Europe Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 166. MEA Metabolic Disorders Drugs Sales, by Country K Unit (2018-2023)
  • Table 167. MEA Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 168. MEA Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 169. MEA Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 170. Middle East Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 171. Middle East Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 172. Middle East Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 173. Africa Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 174. Africa Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 175. Africa Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 176. North America Metabolic Disorders Drugs Sales, by Country K Unit (2018-2023)
  • Table 177. North America Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 178. North America Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 179. North America Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 180. United States Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 181. United States Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 182. United States Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 183. Canada Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 184. Canada Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 185. Canada Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 186. Mexico Metabolic Disorders Drugs Sales, by Type K Unit (2018-2023)
  • Table 187. Mexico Metabolic Disorders Drugs Sales, by Application K Unit (2018-2023)
  • Table 188. Mexico Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2018-2023)
  • Table 189. Metabolic Disorders Drugs: by Type(USD/Units)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Metabolic Disorders Drugs: by Type(USD Million)
  • Table 199. Metabolic Disorders Drugs Glycogen Metabolism Disease Drug , by Region USD Million (2025-2030)
  • Table 200. Metabolic Disorders Drugs Lipid Metabolism Disease Drug , by Region USD Million (2025-2030)
  • Table 201. Metabolic Disorders Drugs Amino Acid Metabolism Drug , by Region USD Million (2025-2030)
  • Table 202. Metabolic Disorders Drugs: by Application(USD Million)
  • Table 203. Metabolic Disorders Drugs Hospital , by Region USD Million (2025-2030)
  • Table 204. Metabolic Disorders Drugs Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 205. Metabolic Disorders Drugs: by Route of Administration(USD Million)
  • Table 206. Metabolic Disorders Drugs Inhalation , by Region USD Million (2025-2030)
  • Table 207. Metabolic Disorders Drugs Injection , by Region USD Million (2025-2030)
  • Table 208. Metabolic Disorders Drugs Other , by Region USD Million (2025-2030)
  • Table 209. South America Metabolic Disorders Drugs, by Country USD Million (2025-2030)
  • Table 210. South America Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 211. South America Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 212. South America Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 213. Brazil Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 214. Brazil Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 215. Brazil Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 216. Argentina Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 217. Argentina Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 218. Argentina Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 219. Rest of South America Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 220. Rest of South America Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 221. Rest of South America Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 222. Asia Pacific Metabolic Disorders Drugs, by Country USD Million (2025-2030)
  • Table 223. Asia Pacific Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 224. Asia Pacific Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 225. Asia Pacific Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 226. China Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 227. China Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 228. China Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 229. Japan Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 230. Japan Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 231. Japan Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 232. India Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 233. India Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 234. India Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 235. South Korea Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 236. South Korea Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 237. South Korea Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 238. Taiwan Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 239. Taiwan Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 240. Taiwan Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 241. Australia Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 242. Australia Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 243. Australia Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 244. Rest of Asia-Pacific Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 245. Rest of Asia-Pacific Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 246. Rest of Asia-Pacific Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 247. Europe Metabolic Disorders Drugs, by Country USD Million (2025-2030)
  • Table 248. Europe Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 249. Europe Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 250. Europe Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 251. Germany Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 252. Germany Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 253. Germany Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 254. France Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 255. France Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 256. France Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 257. Italy Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 258. Italy Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 259. Italy Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 260. United Kingdom Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 261. United Kingdom Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 262. United Kingdom Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 263. Netherlands Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 264. Netherlands Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 265. Netherlands Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 266. Rest of Europe Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 267. Rest of Europe Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 268. Rest of Europe Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 269. MEA Metabolic Disorders Drugs, by Country USD Million (2025-2030)
  • Table 270. MEA Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 271. MEA Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 272. MEA Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 273. Middle East Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 274. Middle East Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 275. Middle East Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 276. Africa Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 277. Africa Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 278. Africa Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 279. North America Metabolic Disorders Drugs, by Country USD Million (2025-2030)
  • Table 280. North America Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 281. North America Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 282. North America Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 283. United States Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 284. United States Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 285. United States Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 286. Canada Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 287. Canada Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 288. Canada Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 289. Mexico Metabolic Disorders Drugs, by Type USD Million (2025-2030)
  • Table 290. Mexico Metabolic Disorders Drugs, by Application USD Million (2025-2030)
  • Table 291. Mexico Metabolic Disorders Drugs, by Route of Administration USD Million (2025-2030)
  • Table 292. Metabolic Disorders Drugs Sales: by Type(K Unit)
  • Table 293. Metabolic Disorders Drugs Sales Glycogen Metabolism Disease Drug , by Region K Unit (2025-2030)
  • Table 294. Metabolic Disorders Drugs Sales Lipid Metabolism Disease Drug , by Region K Unit (2025-2030)
  • Table 295. Metabolic Disorders Drugs Sales Amino Acid Metabolism Drug , by Region K Unit (2025-2030)
  • Table 296. Metabolic Disorders Drugs Sales: by Application(K Unit)
  • Table 297. Metabolic Disorders Drugs Sales Hospital , by Region K Unit (2025-2030)
  • Table 298. Metabolic Disorders Drugs Sales Retail Pharmacy , by Region K Unit (2025-2030)
  • Table 299. Metabolic Disorders Drugs Sales: by Route of Administration(K Unit)
  • Table 300. Metabolic Disorders Drugs Sales Inhalation , by Region K Unit (2025-2030)
  • Table 301. Metabolic Disorders Drugs Sales Injection , by Region K Unit (2025-2030)
  • Table 302. Metabolic Disorders Drugs Sales Other , by Region K Unit (2025-2030)
  • Table 303. South America Metabolic Disorders Drugs Sales, by Country K Unit (2025-2030)
  • Table 304. South America Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 305. South America Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 306. South America Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 307. Brazil Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 308. Brazil Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 309. Brazil Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 310. Argentina Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 311. Argentina Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 312. Argentina Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 313. Rest of South America Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 314. Rest of South America Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 315. Rest of South America Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 316. Asia Pacific Metabolic Disorders Drugs Sales, by Country K Unit (2025-2030)
  • Table 317. Asia Pacific Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 318. Asia Pacific Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 319. Asia Pacific Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 320. China Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 321. China Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 322. China Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 323. Japan Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 324. Japan Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 325. Japan Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 326. India Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 327. India Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 328. India Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 329. South Korea Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 330. South Korea Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 331. South Korea Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 332. Taiwan Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 333. Taiwan Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 334. Taiwan Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 335. Australia Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 336. Australia Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 337. Australia Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 338. Rest of Asia-Pacific Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 339. Rest of Asia-Pacific Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 340. Rest of Asia-Pacific Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 341. Europe Metabolic Disorders Drugs Sales, by Country K Unit (2025-2030)
  • Table 342. Europe Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 343. Europe Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 344. Europe Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 345. Germany Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 346. Germany Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 347. Germany Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 348. France Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 349. France Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 350. France Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 351. Italy Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 352. Italy Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 353. Italy Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 354. United Kingdom Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 355. United Kingdom Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 356. United Kingdom Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 357. Netherlands Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 358. Netherlands Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 359. Netherlands Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 360. Rest of Europe Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 361. Rest of Europe Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 362. Rest of Europe Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 363. MEA Metabolic Disorders Drugs Sales, by Country K Unit (2025-2030)
  • Table 364. MEA Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 365. MEA Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 366. MEA Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 367. Middle East Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 368. Middle East Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 369. Middle East Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 370. Africa Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 371. Africa Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 372. Africa Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 373. North America Metabolic Disorders Drugs Sales, by Country K Unit (2025-2030)
  • Table 374. North America Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 375. North America Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 376. North America Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 377. United States Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 378. United States Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 379. United States Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 380. Canada Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 381. Canada Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 382. Canada Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 383. Mexico Metabolic Disorders Drugs Sales, by Type K Unit (2025-2030)
  • Table 384. Mexico Metabolic Disorders Drugs Sales, by Application K Unit (2025-2030)
  • Table 385. Mexico Metabolic Disorders Drugs Sales, by Route of Administration K Unit (2025-2030)
  • Table 386. Metabolic Disorders Drugs: by Type(USD/Units)
  • Table 387. Research Programs/Design for This Report
  • Table 388. Key Data Information from Secondary Sources
  • Table 389. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Metabolic Disorders Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Metabolic Disorders Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Metabolic Disorders Drugs: by Route of Administration USD Million (2018-2023)
  • Figure 7. South America Metabolic Disorders Drugs Share (%), by Country
  • Figure 8. Asia Pacific Metabolic Disorders Drugs Share (%), by Country
  • Figure 9. Europe Metabolic Disorders Drugs Share (%), by Country
  • Figure 10. MEA Metabolic Disorders Drugs Share (%), by Country
  • Figure 11. North America Metabolic Disorders Drugs Share (%), by Country
  • Figure 12. Global Metabolic Disorders Drugs: by Type K Unit (2018-2023)
  • Figure 13. Global Metabolic Disorders Drugs: by Application K Unit (2018-2023)
  • Figure 14. Global Metabolic Disorders Drugs: by Route of Administration K Unit (2018-2023)
  • Figure 15. South America Metabolic Disorders Drugs Share (%), by Country
  • Figure 16. Asia Pacific Metabolic Disorders Drugs Share (%), by Country
  • Figure 17. Europe Metabolic Disorders Drugs Share (%), by Country
  • Figure 18. MEA Metabolic Disorders Drugs Share (%), by Country
  • Figure 19. North America Metabolic Disorders Drugs Share (%), by Country
  • Figure 20. Global Metabolic Disorders Drugs: by Type USD/Units (2018-2023)
  • Figure 21. Global Metabolic Disorders Drugs share by Players 2023 (%)
  • Figure 22. Global Metabolic Disorders Drugs share by Players (Top 3) 2023(%)
  • Figure 23. Global Metabolic Disorders Drugs share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co., Inc (United States) Revenue: by Geography 2023
  • Figure 27. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 29. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 31. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 33. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2023
  • Figure 35. Kowa Pharmaceuticals America, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Kowa Pharmaceuticals America, Inc (United States) Revenue: by Geography 2023
  • Figure 37. LG Life Science (South Korea) Revenue, Net Income and Gross profit
  • Figure 38. LG Life Science (South Korea) Revenue: by Geography 2023
  • Figure 39. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2023
  • Figure 41. Global Metabolic Disorders Drugs: by Type USD Million (2025-2030)
  • Figure 42. Global Metabolic Disorders Drugs: by Application USD Million (2025-2030)
  • Figure 43. Global Metabolic Disorders Drugs: by Route of Administration USD Million (2025-2030)
  • Figure 44. South America Metabolic Disorders Drugs Share (%), by Country
  • Figure 45. Asia Pacific Metabolic Disorders Drugs Share (%), by Country
  • Figure 46. Europe Metabolic Disorders Drugs Share (%), by Country
  • Figure 47. MEA Metabolic Disorders Drugs Share (%), by Country
  • Figure 48. North America Metabolic Disorders Drugs Share (%), by Country
  • Figure 49. Global Metabolic Disorders Drugs: by Type K Unit (2025-2030)
  • Figure 50. Global Metabolic Disorders Drugs: by Application K Unit (2025-2030)
  • Figure 51. Global Metabolic Disorders Drugs: by Route of Administration K Unit (2025-2030)
  • Figure 52. South America Metabolic Disorders Drugs Share (%), by Country
  • Figure 53. Asia Pacific Metabolic Disorders Drugs Share (%), by Country
  • Figure 54. Europe Metabolic Disorders Drugs Share (%), by Country
  • Figure 55. MEA Metabolic Disorders Drugs Share (%), by Country
  • Figure 56. North America Metabolic Disorders Drugs Share (%), by Country
  • Figure 57. Global Metabolic Disorders Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Merck & Co., Inc (United States)
  • Novartis International AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • AstraZeneca plc (United Kingdom)
  • C.H. Boehringer Sohn AG & Ko. KG (Germany)
  • Kowa Pharmaceuticals America, Inc (United States)
  • LG Life Science (South Korea)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
Select User Access Type

Key Highlights of Report


Apr 2024 230 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Metabolic Disorders Drugs Market Quantitative research analysis
Global Metabolic Disorders Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck & Co., Inc (United States), Novartis International AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca plc (United Kingdom), C.H. Boehringer Sohn AG & Ko. KG (Germany), Kowa Pharmaceuticals America, Inc (United States), LG Life Science (South Korea) and Mitsubishi Tanabe Pharma Corporation (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements in Drug Delivery Technologies" is seen as one of major influencing trends for Metabolic Disorders Drugs Market during projected period 2023-2030.
The Metabolic Disorders Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Metabolic Disorders Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Psoriasis Drug Comprehensive Study by Type (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies), Application (Packaging, Automotive, Building and Construction), Route of Administration...
$ 3450
Depression Drugs Comprehensive Study by Type (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin...
$ 3750
Ulcerative Colitis Comprehensive Study by Application (Hospital, Drugs Stores), Route of Administration (Oral, Injection), Disease level (Mild, Moderate, Severe), Ulcerative Colitis (Ulcerative proc...
$ 3650
Etoposide Comprehensive Study by Type (Etoposide for Injection, Etoposide for Oral Use), Application (Small Cell Lung Cancer, Testicular Cancer), Distribution Channel (Hospital Pharmacies, Retail Pha...
$ 3350
Soliris Drug Comprehensive Study by Type (Plasma Exchange, Plasma Infusion), Application (PNH, AHUS, HPP, GMG, Other), End-User (Pharmaceutical, Hospital, R&D labs, Others) Players and Region - Globa...
$ 3500
Sugar Sphere Comprehensive Study by Type (Micrometers, Standard spheres), Application (Tablets, Capsules), Form Type (Crystal, Granules) Players and Region - Global Market Outlook to 2029
$ 3500